Effects of lysophosphatidic acid on ischemia/reperfusion injury and TRPV1 expression in isolated mouse heart
- Author:
Zhao-Fei LUO
1
;
Chao WU
1
;
Shi-Yun JIN
1
;
Ye ZHANG
1
;
Shu-Fang HE
1
Author Information
- Publication Type:Journal Article
- Keywords: isolated heart; lactate dehydrogenase; Langendorff; lysophosphatidic acid; myocardial ischemia-reperfusion injury; transient receptor potential vanilloid 1
- From: Chinese Pharmacological Bulletin 2022;38(3):417-421
- CountryChina
- Language:Chinese
- Abstract: Aim To investigate the effects of lysophosphatidic acid on ischemia / reperfusion injury(IRI)and TRPV1 expression in isolated mouse heart.Methods The IRI model of isolated mouse heart was established by Langendorff device.The hearts in sham group were continuously perfused for 100 min.The hearts in IR group were stabilized for 10 min followed by no perfusion for 30 min and reperfusion for 60 min.Exogenous LPA was added in the K-H solution during IR in IR+LPA group while HA130, an LPA synthesis inhibitor, was intraperitoneally injected before IR in IR+HA130 group.The infarct volume was measured by TTC staining, the determination of LPA and LDH levels in coronary effluent and LPA concentration in serum was measured by ELISA method.Finally, the expression levels of pTRPV1/TRPV1 and Bcl-2/Bax in myocardial tissues were determined by Western blot.Results Compared with sham group, IR caused evident myocardial infarction and increased the levels of LDH and LPA in coronary effluent.The increase of LPA was linearly correlated with myocardial infarction volume.In addition, the protein levels of pTRPV1 and TRPV1 in myocardium increased, while the ratio of Bcl-2/Bax decreased.The myocardial injury in IR+LPA group was aggravated.In contrast, myocardial IRI was reversed in IR+HA130 group.Conclusions Myocardial ischemia-reperfusion induces the release of LPA, which aggravates myocardial post-ischemic injury, while the inhibition of LPA release exerts cardioprotective effects.The underlying mechanisms might be related to the regulation on cardiac TRPV1 expression and apoptotic signals.
